Trellus Management Company’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Trellus Management Company’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-118	Closed	-$162K	–	139
2014 Q2	$162K	Sell	118 -48	-29%	-$55.7K	0.14%	109
2014 Q1	$230K	Buy	+166	New	+$193K	0.2%	96
2013 Q4	–	Sell	-169	Closed	-$176K	–	118
2013 Q3	$176K	Buy	+169	New	+$181K	0.22%	87

Other funds holding VIRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCP

Lamond Capital Partners San Francisco, California $14.3M AUM 30.74% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Trellus Management Company's VIRX Position: Q3 2014 in Review

Trellus Management Company sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2014, closing a stake of 118 shares — an estimated $162K sold.

Trellus Management Company first reported a position in VIRX in Q3 2013 and held it in 3 quarters. The position peaked at $230K in Q1 2014. 104 funds tracked by Wall St. Rank hold VIRX as of Q3 2014.

Trellus Management Company reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2014 after selling out during the quarter.
Trellus Management Company sold 118 Viracta Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $162K.
Trellus Management Company first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2013 and held it in 3 quarters.
Trellus Management Company's Viracta Therapeutics, Inc. Common Stock position peaked at $230K in Q1 2014.
104 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2014.

Based on Trellus Management Company's 13F filing for Q3 2014, filed 13 Nov 2014.